Key result
Anticoagulant agents used for venous thromboembolism treatment require in-depth knowledge of their distinct pharmacologic properties, pharmacokinetics, and side effect profiles to ensure safe patient management.
Provides a comprehensive overview of the pharmacology, dosing, and monitoring of anticoagulants for VTE to guide safe and effective patient management.
Highlights need for anticoagulant pharmacologic knowledge in VTE; leaves open effects on real-world safety outcomes.
Anticoagulant drugs are the foundation of therapy for patients with VTE. While effective therapeutic agents, anticoagulants can also result in hemorrhage and other side effects. Thus, anticoagulant therapy selection should be guided by the risks, benefits and pharmacologic characteristics of each agent for each patient. Safe use of anticoagulants requires not only an in-depth knowledge of their pharmacologic properties but also a comprehensive approach to patient management and education. This paper will summarize the key pharmacologic properties of the anticoagulant agents used in the treatment of patients with VTE.
No takes yet. Share an insight, caveat, or question.
Nutescu et al. (2016) conducted a review in Venous thromboembolism. Anticoagulants was evaluated. Anticoagulant agents used for venous thromboembolism treatment require in-depth knowledge of their distinct pharmacologic properties, pharmacokinetics, and side effect profiles to ensure safe patient management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: